Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778138 | 0.85 | HTR2A (0.43) | HTR2AHTR2CTRPV4SMN1; SMN2PKM | |
| SCHEMBL12778129 | 0.78 | KDM4E (0.56) | HTR2AHTR2CTRPV4SMN1; SMN2PKM | |
| SCHEMBL14530321 | 0.77 | TDO2 (0.58) | HTR2AHTR2CTRPV4PKMTDO2 | |
| SCHEMBL12778135 | 0.77 | ALOX5AP (0.41) | HTR2AHTR2CSMN1; SMN2AKR1C3PKM | |
| SCHEMBL12778097 | 0.77 | KDM4E (0.58) | HTR2AHTR2CSMN1; SMN2PKMTDO2 | |
| SCHEMBL12778084 | 0.77 | KDM4E (0.58) | HTR2AHTR2CSMN1; SMN2PKMTDO2 | |
| SCHEMBL12778088 | 0.76 | HTR2A (0.49) | HTR2AHTR2CTRPV4SMN1; SMN2PKM | |
| SCHEMBL694087 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2AKR1C3ALOX5APFEN1KDM4E | |
| SCHEMBL12778131 | 0.72 | HTR2A (0.44) | HTR2AHTR2CTRPV4SMN1; SMN2GPR183 | |
| SCHEMBL1271815 | 0.71 | EPAS1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902182-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902182-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2007059229-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070111985-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111985-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111985-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | HTR2A 4074/4885HTR2C 4122/4885TRPV4 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.